30 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler
- RxCUI
- 2395774
- RxNorm name
- 30 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler
- Display name
- 30 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler
- Full name
- 30 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler
- Term type
- SCD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:17
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Trelegy Ellipta | FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE | GlaxoSmithKline LLC | b5a81d5a-4648-4c7a-951d-33c014a63c7e | 2023-06-02 | Warnings, Adverse reactions | 2395774 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| b5a81d5a-4648-4c7a-951d-33c014a63c7e | fluticasone furoate 200 MCG/ACTUAT / umeclidinium 62.5 MCG/ACTUAT / vilanterol 25 MCG/ACTUAT Dry Powder Inhaler, 30 ACTUAT [PSN] · 30 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [SCD] · fluticasone furoate 200 MCG/ACTUAT / umeclidinium (as umeclidinium Br) 62.5 MCG/ACTUAT / vilanterol (as vilanterol trifenatate) 25 MCG/ACTUAT Dry Powder Inhaler, 30 ACTUAT [SY] | 3 | 14 | These highlights do not include all the information needed to use TRELEGY ELLIPTA safely and effectively. See full prescribing information for TRELEGY ELLIPTA. TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), for oral inhalation use Initial U.S. Approval: 2017 | 20230602 |